Deals, Development and Manufacturing

Pfizer to Acquire Biohaven Pharmaceuticals for $11.7 Billion

May 16, 2022

Pfizer will acquire Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in migraine treatments, for $11.7 billion.

Avantor and Cytovance Biologics Partner on Plasmid DNA Development

May 13, 2022

Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.

Lonza and Integral Molecular Enter Biotherapeutics De-Risking Collaboration

May 09, 2022

Lonza and Integral Molecular will collaborate to better assess the risks of off-target binding of biologic drug candidates.

Sanofi and Seagen Announce ADC Development Collaboration

March 18, 2022

Sanofi and Seagen have entered an agreement to investigate three cancer targets.

Flow Eighteen38 Receives €5 Million (US$5.58 Million) to Expand Production and Biophysical Capabilities

March 14, 2022

Flow Eighteeen38 is receiving a €5 million (US$5.58 million) investment from its parent company, FairJourney Biologics.

evitria Licenses mAbsolve Gene Silencing Technology

March 14, 2022

Evitria has entered into an agreement with mAbsolve that will allow the company to use mAbsolve’s gene silencing technology in their antibody cells.

Voyager Therapeutics Announces License Agreement with Novartis Worth Up to $1.75 Billion

March 11, 2022

Novartis will pay Voyager up to $1.75 billion for access to Voyager’s novel Tracer AAV capsids for potential use with three CNS targets.

Element Biosciences Partners with Genoox on Validation Project

March 04, 2022

Genoox will use their genomic data platform to validate Element's AVITI system.

Thermo Fisher Scientific Extends Collaboration Support for Biopharma Discovery and Development

March 03, 2022

Thermo Fisher and Symphogen have extended their collaboration involving improved data workflow, which supports the discovery and development of new cancer treatments.

IDT Biologika and Exothera Partner on Viral Vaccines Manufacturing

March 03, 2022

Under a collaboration, IDT Biologika and Exothera will conduct feasibility studies on scaling up the manufacturing process for viral vector-based vaccines.